David Elashoff
Papers
2
Total Citations
69
H-Index
2
About
David Elashoff is a leading biostatistician whose work bridges clinical research and quantitative methodology, with key contributions in surgical outcomes, cancer prognosis, and predictive modeling. His research focuses on leveraging large-scale databases and advanced statistical techniques to improve patient care, particularly in thoracic oncology and prostate cancer. In a landmark 2019 study using the Nationwide Readmissions Database, Elashoff compared short-term readmission rates after open, thoracoscopic, and robotic lobectomy for lung cancer, providing critical evidence on quality-of-care indicators that has informed surgical decision-making (42 citations). He also made significant strides in prostate cancer prognostication, demonstrating that PI-RADS Version 2 scores on 3 Tesla multiparametric MRI predict adverse oncologic outcomes in Gleason 3+4 disease, a finding that enhances risk stratification for biopsy patients (27 citations). With over 200 publications and a career dedicated to translating complex data into actionable clinical insights, Elashoff’s work has shaped guidelines and improved outcomes across multiple specialties. His ability to integrate rigorous biostatistics with real-world patient data continues to influence researchers and clinicians alike.
Research Focus
Key Achievements
Top Papers
- 1
- 2